Solar stocks drop sharply as Senate Republicans detail changes to Trump’s tax-and-spending bill that would phase out solar, ...

Eli Lilly is taking a big swing into gene editing with a deal to buy Verve (NASDAQ:VERV) Therapeutics for up to $1.3 billion, ...

The deal centers around a medicine that could “shift the treatment paradigm for cardiovascular disease,” Lilly said, but also ...

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Verve Therapeutics, Inc. (NASDAQ: VERV) to Eli Lilly and Company is fair to Verve shareholders. Under the terms of ...

Wall Street’s main indexes slipped on Tuesday as the Israel-Iran conflict entered its fifth day, denting global investor ...

U.S. stocks are drifting lower, while oil prices are rising again. The S&P 500 fell 0.3% Tuesday. The Dow Jones Industrial ...

Verve is developing drug candidates for heart disease, including the PCSK9-targeted VERVE-102, a base-editing therapy.

S&P 500 dips on weak retail sales and Iran conflict fears. Will the Fed’s rate decision and rising oil prices drive more volatility this week?